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A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden
clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to
the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was
modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using
the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal.
A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in
the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3)
required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist;
sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic
symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia
secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.
1. Introduction
The literature has clearly established that antipsychotics can
cause catatonia [1, 2]. Catatonia cases secondary to the
intake of both first-generation [1–3] and second-generation
antipsychotics [2, 4] have been described. There may be
a spectrum between antipsychotic-induced catatonia and
neurolepticmalignant syndrome (NMS) [5–7].The incidence
of NMS has been reduced after the introduction of second-
generation antipsychotics [7]. A differential characteristic
from clozapine is that it has been associated with NMS only
on rare occasions. In a review of 68 published NMS cases
associated with second-generation antipsychotics, there were
21 clozapine cases [8]. Most of the NMS cases associated
with clozapine demonstrated atypical presentations [8, 9]. In
spite of these cases, clozapine may be the best antipsychotic
for rechallenging patients who developed NMS with other
antipsychotics [10]. Manu et al. [11] reviewed the cases of five
clozapine-inducedNMSpatients whowere rechallengedwith
clozapine using slow titrations and creatinine kinase (CK)
monitoring; all five rechallenges were successful and did not
result in NMS.
Another characteristic which makes clozapine appear
different from the majority of antipsychotics is that abrupt
clozapine discontinuation is frequently associated with with-
drawal symptoms [12]. Clozapine is characterized by block-
ing multiple receptors including the dopamine, muscarinic,
serotonergic, histaminic, and 𝛼1 adrenergic receptors. In a
review on clozapine withdrawal, Verghese et al. [12] proposed
that time course and clinical features of clozapine withdrawal
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Do you suspect a drug 
reaction from sudden 
withdrawal of clozapine?
What is the probability 
the catatonia is caused 
by an underlying illness?
Did catatonia recur 
when clozapine was 
withdrawn at a 
subsequent time?
Is there a past history of 
catatonia being induced 
after clozapine 
withdrawal?
Definite 
Yes
Yes or unassessable 
Did catatonia 
symptoms improve 
with readministration
of clozapine or with 
catatonia treatment?
Low
No
No
Did catatonia 
develop after 
withdrawal of 
clozapine in 2 
weeks or less?
Yes
Unlikely
No
Were preexisting catatonia 
symptoms exacerbated by 
withdrawal of clozapine?
No
No
Yes
Did the catatonia cause 
long term disability or 
impairment?
No
Yes
Yes Yes
High or 
unsure
Is there any objective 
evidence in support of 
an ADR as the causal 
mechanism?
Yes
Has clozapine withdrawal 
been reported to cause 
catatonia? 
Yes
No
No
No
Possible
Probable
Figure 1: Modification of the Liverpool Adverse Drug Reaction Causality Assessment Tool [25] to retrospectively assess the likelihood that
clozapine withdrawal caused the catatonia episode.
may be explained by cholinergic overdrive and gamma-
aminobutyric acid (GABA) supersensitivity. After clozapine
withdrawal, some individuals have symptoms suggestive of
a cholinergic rebound including nausea, vomiting, diar-
rhea, headache, agitation, confusion, and diaphoresis. These
symptoms are probably explained by the antimuscarinic
properties of clozapine and appear to respond to anti-
cholinergic treatment [13]. Other individuals appear to have
worsening psychosis and/or abnormalmovements [14].More
importantly, in very rare instances, clozapine withdrawal has
been associated with catatonic symptoms [15–24]. Table 1
describes the 9 cases that we identified in a PubMed search
(Footnote 1). Catatonia episodes were rediagnosed using
the Diagnostic and Statistical Manual, 5th Edition (DSM-5).
The Liverpool Adverse Drug Reaction Causality Assessment
Tool (LADRCAT) is used to assess adverse drug reaction
(ADR) causality [25]. Wemodified it to retrospectively assess
ADRs secondary to drug withdrawal. Then, we used the
Modified LADRCAT (MLADRCAT) (Figure 1) to establish
the likelihood that clozapine withdrawal caused the cata-
tonia episodes in prior published cases (last column in
Table 1) and in our patient who developed three catatonic
episodes after three instances of sudden clozapine withdraw-
al.
2. Case Presentation
2.1. Assessments
2.1.1. Assessments Using DSM-5 Catatonia Criteria. The
DSM-5 Criterion A requires having ≥3 of the 12 listed cata-
tonic symptoms needed to make the diagnosis. After review-
ing all available information, the first and last authors
discussed and agreed on the presence of DSM-5 Criterion
A in our patient and in 7 of 9 of the previously published
cases.
2.1.2. The MLADRCAT. The LADRCAT [25] allows the
diagnosis of an adverse drug reaction (ADR) while a drug
is used for treatment, but it provides no system for diag-
nosing an ADR after drug withdrawal. To retrospectively
assess the likelihood that clozapine withdrawal caused the
catatonia episode, we modified the scale (MLADRCAT).
This modified scale established the probability that clozapine
withdrawal explained the three catatonic episodes of our
patient (Figures S10–S12 in Supplementary Material avail-
able online at https://doi.org/10.1155/2017/2402731) and the
catatonic episodes of previously published cases (Figures
S1–S9).
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Catatonia
Clozapine
Age
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
Admissions to PHＭ1
Admissions to ．（2
Figure 2: Longitudinal course of our patient including catatonic episodes, clozapine trials, and admissions to psychiatric facilities. 1Psychiatric
hospitals. 2Nursing home.
2.1.3. Laboratory Studies. The commercial laboratory tests
routinely used by the psychiatric state hospital were employed
to measure trough steady-state serum clozapine and nor-
clozapine concentrations in ng/mL. The mean ± standard
deviation (SD) for serum concentrations is described for
clozapine, norclozapine, and the total (adding both). The
recommended therapeutic range for trough serum clozapine
concentration is 350–600 ng/mL [26]. Serum CK levels (nor-
mal laboratory range: 21–232 IU/L) were used as an objective
measure of catatonia severity [27].
2.2. Prior History
2.2.1. Description of the Patient. The patient was a single,
unemployed, African American male with a psychiatric
history of longstandingDSM-5 schizophrenia.Hewas treated
with haloperidol decanoate and had a history of mixed
substance abuse (including alcohol, cocaine, and Cannabis)
but did not smoke tobacco. The patient had a family history
positive for schizophrenia in a brother and paternal uncle. He
graduated from high school. His history included multiple
arrests and revolving door admissions (Figure 2).
His psychiatric treatment first started as an outpatient
with haloperidol decanoate at 18 years of age. His first
psychiatric admission to the first state psychiatric hospital
was at the age of 27 and lasted almost 1 month. His second
admission was at the age of 30 and lasted 6 days. He had no
catatonic symptoms during these first two admissions.
The third hospitalization at the age of 30 was a result
of medication noncompliance in the community. On day 1
of the third admission (used as day 1 of the long follow-up
of this patient), his presenting symptoms included markedly
disorganized thinking, bizarre behavior, poor self-care, social
withdrawal, aggressiveness towards his brother, suspicion,
and hallucinations leading to an involuntary admission per
court order. During this admission, he was also diagnosed
with obesity, hypertension, and dyslipidemia. The medical
treatment included hydrochlorothiazide 25mg/day on day
281. On day 438, two medications were added: simvas-
tatin 20mg/day and metoprolol 12.5mg/day (increased to
100mg/day on day 460).
During this third hospital admission, the patient’s symp-
toms remained refractory to high doses of oral and decanoate
haloperidol, olanzapine, and high doses of risperidone.
Clozapine was started on day 190 at 25mg/day and a stable
dose of 400mg/day was reached on day 228. Clozapine
provided some improvement for the patient’s symptoms.
On day 392, a Mini-Mental Status Examination (MMSE)
was administered to the patient with scores of 29/30 with
WORLD backwards and 27/30 with serial 7s on the MMSE.
This score is normal for his age and education [28]. On
the MMSE, the abnormal results were serial 7s (3/5) and
copying the two intersecting pentagons incorrectly. Brief
Psychiatric Rating Scale-Anchored (BPRS-A) [29] provided
a score of 37; abnormal items were severe suspiciousness,
severe unusual thought content, moderately severe bizarre
behavior, mild self-neglect, moderately severe disorienta-
tion, mild conceptual disorganization, moderately severe
blunted affect, and moderate mannerisms and posturing.
An Abnormal Involuntary Movement Scale (AIMS) exam
[30] demonstrated some minimal movements in the tongue
and lower 2 extremities and mild movements in the upper
extremities.
2.2.2. Clozapine Treatment in the First Year. He received an
aripiprazole augmentation trial of clozapine from day 442 to
day 532 up to 30mg/day and of quetiapine up to 600mg/day
from day 532 to day 631. Then, the process of switching
augmentation from quetiapine to ziprasidone was started on
day 631.
2.3. First Catatonic Episode at 33 Years of Age during theThird
Psychiatric Admission
2.3.1. Clozapine Treatment Leading to the First Catatonic
Episode. On day 659 when he was taking clozapine
400mg/day (plus 200mg/day of quetiapine and ziprasidone
120mg/day), he ran away and had no access to any psychiatric
(or medical) medication in the community.
During the prior 14 months when he was taking
400mg/day of clozapine, his serum clozapine concentration
was 511 ± 79 (range: 372–675), norclozapine concentration
was 383±80 (range: 194–507), and total clozapine concentra-
tion was 894 ± 129 (range: 566–1061).
2.3.2. Catatonic Episode after the First Clozapine Withdrawal.
On day 672, 14 days after running away from the psychiatric
hospital and not receiving any other clozapine dose, he was
arrested by the police and incarcerated; then, he was taken to
the university hospital. He was diagnosed with dehydration,
hypernatremia, hypochloremia, rhabdomyolysis, catatonic
schizophrenia, hypertension, and hyperlipidemia. He had
a normal head computerized tomography (CT) scan. The
urine drug screen was positive only for clozapine; sodium
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was 150mEq/L; chloride was 113mEq/L; and he had an
elevated CK of 1838 IU/L which decreased to 823 IU/L during
admission. He was treated supportively with fluids. On day
673, he was discharged back to jail. Within 24 hours, he
was found unresponsive and with urinary incontinence and
was sent back to the university hospital on day 674. There,
he was treated intermittently with doses of intravenous
(IV) lorazepam 1mg (we are unsure of the total dose) and
quetiapine 25mg/day. The patient refused food and drink
during the entirety of the admission at the university hospital.
On day 678, he was transferred back to the psychiatric state
hospital where he presented limited interaction with his
environment, poor eye contact, posturing of the left arm,
stereotypic movement in the fingers, negativistic behavior,
and bursts of dyskinetic movements. He was oppositional to
any movements in all directions.
2.3.3. TreatmentwithHighDoses of Lorazepamduring the First
Catatonic Episode. On day 678, he arrived at the psychiatric
hospital. He received 4mg lorazepam intramuscularly (IM)
and within two hours he began drinking and he was able
to take some steps and sit in a chair. He was psychotic and
disoriented to location. Three hours later, he received 4mg
lorazepam (a total of 8mg for day 678).
The next day (day 679), he received a total of 14mg of
lorazepam with minimal results. He was able to eat; how-
ever, he had urinary incontinence and a paucity of speech.
On day 680, the patient appeared worse and was started
on lorazepam 16mg/day. There was mild improvement in
catatonic symptoms; he was able to say two sentences every 5
minutes and was able to stand up and walk with help. He was
also able to eat unassisted. After day 681, lorazepam 16mg/day
was scheduled until day 698. He was slowly improving and
at times became hostile and possibly psychotic. On day
683, ziprasidone 80mg/day was started for these symptoms;
however, it was discontinued the next day. Over the next
week, the patient’s catatonic symptoms improved but he only
mumbled “OK” when spoken to.
Lorazepamwas reduced to 8mg/daywithin 1month of his
catatonic presentation (on day 700). The patient was tapered
to 2mg/day over the next few weeks; however, his symptoms
exacerbated and he was kept on 4mg/day for the next few
months. Lorazepam was eventually switched to clonazepam,
which was finally discontinued on day 1332.
2.3.4. Time between the First and Second Catatonic Episodes.
Thepatient remained catatonia-free during the next 2 years of
his admission before he was discharged on day 1517. He was
discharged on 400mg/day of clozapine.
His fourth admission to the psychiatric hospital, 3months
after discharge, lasted 3 months. His discharge psychiatric
medications included clozapine 600mg/day, oral haloperidol
15mg/day, 100mg of haloperidol decanoate every 3 weeks,
and benztropine 2mg/day at night. His fifth admission to
the psychiatric hospital was seven months later and lasted 2
months. His dischargemedications did not include clozapine.
His sixth admission to the psychiatric hospital was 7 months
later and lasted 10 months. His discharge medications from
the sixth admission included clozapine 600mg/day and
diphenhydramine 50mg at night. In summary, during these
3 admissions, he did not have catatonic symptoms.
2.4. Second Catatonic Episode at 37 Years of
Age (111.1 Kg) Leading to the 7th Psychiatric Admission
2.4.1. Clozapine Treatment Leading to the Second Catatonic
Episode. The patient was readmitted to the psychiatric hos-
pital 18 days after the last discharge (6th admission) when the
police brought him in after he was discovered sitting on the
street for 8-9 hours that day.
2.4.2. Second Catatonic Episode after Clozapine Withdrawal.
On arrival at the psychiatric hospital on day 2509, the patient
did not speak or move, he appeared to be responding to
internal stimuli, he maintained poor eye contact, and he
was malodorous and dirty. The patient had an elevated
temperature (38.9∘C), lower extremity edema, elevated heart
rate and blood pressure, and a CK of 1943 IU/L.
2.4.3. Treatment withHighDoses of Lorazepam during the Sec-
ond Catatonic Episode. He was sent to the emergency room
at the university hospital the next day and was transferred to
the intensive care unit where hewas treatedwith IV fluids and
IV antibiotics for a urinary tract infection. He was given 1mg
of lorazepam IV and then doses of 1 or 2mg IV every 2 hours
reaching up to 24mg/day.Hewas also treatedwith a clonidine
patch 0.1mg/day and subcutaneous heparin 1500 units/day
for preventing deep vein thrombosis. Head CT scan and
echocardiogram were normal. After 5 days, he was returned
to the psychiatric hospital after the CK was normalized.
On day 2514 when he came back to the psychiatric
hospital, he was prescribed 22mg/day IM lorazepam. The
lorazepam taper tookmore than 3months because there were
4 episodes suggestive of catatonic decompensation which
required increasing the lorazepam dose again. Finally, on day
2649, lorazepam was completely and definitively stopped.
2.4.4. Time between the Second and Third Catatonic Episodes.
On day 2649, the same day lorazepam was discontinued,
clozapine 50mg/day was started. It was increased up to
400mg/day on day 2720.
2.5. Third Catatonic Episode at the Age of 38 Years (132.3 Kg)
Leading to the 8th Psychiatric Admission
2.5.1. Clozapine Treatment Leading to the Third Catatonic
Episode. On day 2903, his discharge medications from the
seventh admission included clozapine 400mg/day.
In the last 4 months, the five measured concentrations
were 624±69 (range: 504–684) for clozapine, 396±97 (range:
253–520) for norclozapine, and 1020 ± 158 (range: 757–1167)
for the total.
2.5.2. Third Catatonic Episode after Clozapine Withdrawal.
Six days after discharge, the patient was arrested and at that
time he had the complete clozapine supply that he was given
on discharge, indicating that he had not taken any clozapine
tablets after leaving the hospital. He spent another 4 days
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in jail; then, after a total of ten days without clozapine, he
was readmitted during his third catatonic episode for his
8th psychiatric admission. While in jail, the patient was
described by law enforcement as not following directions
or answering questions. He was brought to the psychiatric
inpatient state hospital on the evening of day 2913 where his
initial assessment described him as mute, not cooperative,
displaying poor eye contact, and paying little attention to
the interviewer. He had reduced psychomotor activity; he
would sit very still; however, he would then abruptly start
pacing around the room, and at one point he was pacing and
then stopped and urinated. He also had some choreoathetoid
movements in his fingers. This catatonic presentation was
similar to the other 2 prior episodes.
2.5.3. Treatment of the Third Catatonic Episode with Benzo-
diazepines and Clozapine. The charted information on the
response to treatment and the justification for the treatment
decisions during this third catatonic episodeweremuchmore
limited than in prior episodes. During the third catatonic
episode, there was a psychiatrist at the psychiatric hospital
who started high doses of IM lorazepam but this treatment
was tapered at the university hospital when the patient was
admitted for serious dehydration.
In the first two days after coming from jail to the
psychiatric hospital on day 2913, the patient refused to take
oral medications and received IM cocktails with lorazepam
2mg, diphenhydramine 50mg, and haloperidol 5mg. On
day 2916, the patient was not eating or drinking, was mute,
refused medications, and had periods of prolonged standing
and staring, along with negativism. He received lorazepam
4mg IM on that day. On the fourth day (day 2917), he
received 12mg of lorazepam IM and on the fifth day (day
2918) he received 16mg of lorazepam IM. He showed clear
signs of dehydration with blood urea nitrogen (BUN) of 32
mMol/L (range: 7–18), a sodium level of 157mEq/L (range:
136–145), and CK elevation to 2307U/L. Due to these lab
abnormalities, on the sixth day (day 2919), the patient was
sent back to the university hospital. His head CT scan was
normal. He was diagnosed with catatonia and given IV fluids,
and within 2 days his CK levels returned back to normal.The
medical hospital discontinued all of his medications except
oral lorazepam which was decreased to 3mg/day.
He was transferred back a second time to the psychiatric
hospital on day 2921. On that day, the patient continued to
portray catatonic symptoms; he would sit still with his lunch
on his lap and not eat even when encouraged by staff. Staff
stated that he did not react to his external environment. He
was prescribed no medication for 4 days. Six days later, he
was prescribed 8mg/day of lorazepam and 400mg/day of
clozapine. He had a third short admission to the university
hospital for less than 2 days.
The patient appeared to improve from the catatonic
symptoms due to the use of lorazepam, but it was used inter-
mittently. Clozapine treatment was started first by adding it
to lorazepam on day 2926.The patient took up to 400mg/day
intermittently until day 2941. During that time, he required
frequent haloperidol and diphenhydramine injections, until
a forced medication order was approved by the court. After
that, a second trial of clozapine was started on day 2976 with
25mg/day and slowly titrated up. His clozapine dose was
slowly increased to 400mg/day (on day 3079) and then to
600mg/day (day 3140). This second clozapine trial led to a
complete and definitive recovery from the catatonic episode.
2.5.4. Stabilization and Final Placement. Shortly after that,
the patient first collaborated with weight measurements,
which indicated that he had lost 25 Kg during the cata-
tonic episode. Before completing the third year of this 8th
admission, on day 3603, at 41 years of age, the patient was
transferred to a state nursing home for psychiatric patients.
His discharge medications were clozapine 700mg/day, meto-
prolol extended release 50mg/day, simvastatin 20mg/day,
memantine 10mg/day, and aspirin 81mg/day. He stayed on
clozapine until day 4084. On day 4129, he was transferred
to another state psychiatric hospital located near the state
nursing home. Since then, he has had another 4 admissions
to this second state psychiatric hospital. The fifth admission
started on day 4974 and has lasted more than 1 year. His
current age is 44 years. Clozapine has never been prescribed
during any of the 5 admissions to this second state psychiatric
hospital.
3. Discussion
3.1. Assessments in Our Case
3.1.1. Assessments by DSM-5 Catatonia Criteria. Each one of
the three catatonic episodes was diagnosed at the time of
presentation and retroactively by us through chart data using
DSM-5 criteria (including negativism, mutism, and stupor).
In all three episodes, CK levels were elevated and medical
hospitalization and intravenous fluids were needed.
3.1.2. Assessments by theMLADRCAT. All the authors agreed
that themodified LADRCATwas definite in all three episodes
indicating that the catatonic episodes were secondary to
clozapine withdrawal. No other catatonic episodes were
described from ages 17 to 42 years, indicating that the patient
did not have any other cause of catatonia.
3.1.3. Clozapine Dose and Serum Concentrations. The first
and third catatonic episodes occurred after sudden with-
drawal from 400mg/day while the second was after with-
drawal from 600mg/day. In the first and second episodes, we
have some idea of the patient’s serum clozapine concentra-
tions before the sudden withdrawal. As far as we can tell, the
patient stopped clozapine suddenly after leaving the hospital
(running away in the first episode or after prior discharge
instances in the second and third episodes). An exact onset
of the catatonic symptoms can only be approximated since
the first and third catatonic episodes started in jail and in
the second episode the patient was brought by the police
after sitting for 8-9 hours on the street. At the hospital, the
catatonic symptoms in the three episodes were definitely
described between 10 and 18 days after sudden withdrawal
of clozapine. After 1 week of sudden discontinuation of
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therapeutic serum clozapine concentrations, clozapine may
disappear completely from the body [31].
3.2. Comparison of the Treatment of the Three Catatonic
Episodes. During the first 2 episodes, the patient was treated
for extended periods of time with high doses of lorazepam.
In the first episode, he received 16mg/day lorazepam for
threeweeks before significant improvements in his symptoms
were documented and the dosage started to be tapered.
During the second catatonic episode, he received up to
24mg/day and slowly improved over a period of months due
to multiple premature tapering attempts of lorazepam. In the
third episode, the patient received 16mg/day for only one day
before being tapered to 8mg/day. Clozapine up to 400mg/day
was prescribed but the patient was noncompliant with it.
After a second and definitive clozapine trial during this third
catatonic episode, the patient recovered completely from the
catatonic symptoms. Due to medication noncompliance and
lack of consistent treatmentwith lorazepamand/or clozapine,
it took almost 3 months before the catatonic symptoms were
resolved, after adding clozapine a second time.
Unlike other similar cases in the literature which required
much lower lorazepam doses for resolution of symptoms,
this patient required very high doses. The authors theorize
that this patient may have required such high doses due
to adaptation and desensitization of the benzodiazepine
receptors due to the low dose exposure of lorazepam. In the
first episode, the patient received 1mg of lorazepam IV as
needed at the university hospital for 4 days; the total dosage
amount is uncertain. In the second episode, the patient
responded to a high dose of 24mg/day, prescribed after the
last author’s recommendation.
3.3. Comparison with Prior Published Cases
3.3.1. Diagnosis of Catatonia. A literature review identified 9
other cases of clozapine-withdrawal catatonia (Tables 1 and
2). In 2 of the 9 cases, we were unable to make the catatonia
diagnosis for the reduced number of symptoms described
in the published articles [22, 23]. In the remaining 7 cases
[15–21], the authors described ≥3DSM-5 catatonia symptoms
(Table 2).
3.3.2. Diagnosis of Catatonic Episode Secondary to Cloza-
pine Withdrawal. The MLADRCAT was applied to the 7
previously published cases of DSM-5-diagnosed catatonia.
Three of the 7 cases were classified as “definite” catatonia
after clozapine withdrawal and four as “probable” (Table 1).
One of the 7 cases was reported to have included catatonia
episodes independent of clozapine withdrawal. In the 7
previously published cases, the onset of catatonic symptoms
after clozapine withdrawal ranged from 1.5 to 7 days versus
10–18 days in our patient (Table 1).
3.3.3. Treatment of Catatonic Episode Secondary to Clozapine
Withdrawal. In the 7 previously published cases, treatment
varied including oral/IM lorazepam, clozapine, and ECT
(Table 2). Resolution of symptoms in the literature ranged
from 4 days to 3 weeks (Table 2). Our patient received
high doses of lorazepam as a treatment for all 3 of his
catatonic episodes; however, during his third episode, he
only received a high lorazepam dose (16mg) for 1 day before
becoming dehydrated and requiring hospitalization. He was
restarted on a lower dose of only 8mg/day lorazepam with
adjunct clozapine 400mg/day taken intermittently due to
noncompliance. He finally recovered from the third catatonic
episode during a second and definitive clozapine trial.
3.3.4. Underlying Psychiatric Disorder Treated with Clozapine.
The psychiatric diagnosis in the 7 previously published cases
included 5 with schizophrenia and 2 with schizoaffective
disorder. Our patient was diagnosed with schizophrenia.
3.4. PharmacologicalMechanismsWhichMay Explain Catato-
nia after Sudden Clozapine Withdrawal. A pharmacological
model of catatonia secondary to clozapine withdrawal is
hypothesized after reviewing three pieces of literature data
suggesting that clozapine may have agonist properties at
the GABA receptors: (1) clozapine studies on GABA neu-
rotransmission; (2) the existence of cases of a rare phar-
macodynamic drug-drug interaction (DDI) when starting
clozapine in patients taking benzodiazepines; and (3) two
cases of clozapine intoxication who responded to flumazenil,
a benzodiazepine antagonist at the GABA receptor.
3.4.1. Clozapine Studies on GABA Neurotransmission. In a
transcranial magnetic stimulation study, Kaster et al. [32]
concluded that clozapine treatment is associated with an
increase in GABAB mediated inhibitory transmission. An in
vitro study described clozapine as inhibiting GABA-evoked
chloride currents at recombinant GABAA receptors [33]. In a
rat study, Bragina et al. [34] suggested that clozapine increases
GABA activity by upregulating vesicular GABA transporters
(VGAT) in the frontal cortex. In an animal study, Marx et
al. [35] proposed a different mechanism that suggests that
clozapine may indirectly increase GABA activity by releasing
the neurosteroid, allopregnanolone. Finally, not all studies
agree that clozapine has GABA agonist properties; in a 2000
in vitro study using a culture of ventral tegmental neurons,
Michel and Trudeau proposed that in that model clozapine
may have an inhibitory effect on GABAA receptors [36].
3.4.2. Clozapine and Benzodiazepine Pharmacodynamic DDI
in Patients. A poorly understood pharmacodynamic DDI
between clozapine and benzodiazepines has been described
in a few individuals, usually leading to severe ADRs within
48 hours after the first clozapine dose in patients taking ben-
zodiazepines. The ADRs secondary to this DDI may include
lethargy, ataxia, loss of consciousness, and, rarely, respiratory
arrest. Sassim and Grohmann [37] first reported two cases;
then, they reviewed 959 patients taking clozapine and found
4 cases of severe cardiovascular and respiratory dysregulation
during the combination of clozapine-benzodiazepines at
the beginning of the clozapine titration [38]. Finkel and
Schwimmer [39] reported 7 cases of respiratory arrest after
treating 12,000 individuals, but only in 2 of these cases did
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Table 2: Details for 7 cases which were considered at least probable catatonic episodes secondary to clozapine withdrawal.
Authors Catatonic symptoms Treatment Other catatonia episodes1
Lee and Robertson [15]
Restless, impulsive aggressive,
disoriented disturbed sleep,
refusal to wear clothing, staring,
periodic posturing mannerisms,
irrelevant speech, and
uncontrollable laughing
Oral lorazepam 8mg/day did not
work
Clozapine restarted 10 days after
catatonia
Symptoms resolved in 3 weeks
No
Yeh et al. [16]
Stupor, mutism, waxy flexibility,
staring, posturing,
negativism, and nil oral intake
Trihexyphenidyl 2–4mg/day
Clozapine restarted to
175mg/day within 2 weeks
Catatonia resolved in 7 days
One future
Bastiampillai et al. [17]
Urine/feces incontinence,
mutism, mannerisms, stupor,
posturing fever, diaphoresis, and
autonomic instability
IM lorazepam unknown dosages
Treated for 48 hours with no
response
ECT response started in the 4th
session
Major improvement in the 10th
session
One past
Thanasan and Jambunathan
[18]
Tremors in upper limbs,
unresponsive to call or
commands,
febrile, flat affect, mute, and
cogwheel and general rigidity
Bromocriptine from 2.5 to
15mg/day (33 days)
Oral diazepam for 6 days
Improvement by day 12
No
Wadekar and Syed [19]
Fixed gaze, minimal withdrawal
from pain, and Bush-Francis
scale score 6/14
Lorazepam 1mg IV with brief
improvement
Lorazepam 3mg/day on days 1
and 2
Restarted on clozapine 25mg/day
on day 2
On 200mg/day of clozapine by
day 5
Rapid improvement on day 4
No
Kumar et al. [20] Nil oral intake, quiet, mutism,posturing, and waxy flexibility
Lorazepam for 2 days
ECT started on day 3 and
improvement after 4 ECTs
Discharged on risperidone
4mg/day
No
Wang et al. [21]
Excitement, mutism, posturing,
staring, negativism, and
echolalia2
Inpatient admission with
clozapine reinstitution
Four on clozapine
withdrawal and five on
lorazepam withdrawal3
ECT: electroconvulsive therapy; IM: intramuscular; IV: intravenous.
1Other catatonic episodes after clozapine withdrawal in the past or the future.
2On four previous occasions in the immediate period following clozapine cessation, the patient developed florid psychotic symptoms in the formof persecutory,
grandiose delusions, disorganized behavior, and auditory hallucinations. She displayed catatonic features (Bush-Francis scale of 20 indicating severe catatonia).
3The patient initially had 4 episodes of catatonia after clozapine withdrawal. Then, she had 5 episodes of catatonia after lorazepam withdrawal, which were the
focus of the article.
the documentation associate them with the combination
of benzodiazepines and the first clozapine doses. Klimke
and Klieser [40] reported that, of 162 individuals treated
with the combination of clozapine and benzodiazepines in
a German hospital, 1 death by respiratory arrest occurred
in an individual suffering from liver impairment. Faisal et
al. [41] reviewed company data and found (1) 6 US cases
of respiratory depression/arrest in combination clozapine-
benzodiazepine treatment in 15,311 clozapine patients and
(2) 10 European cases of cardiorespiratory arrest within
the first 3 days (some taking benzodiazepines) in 63,000
patients. Bitter et al. [42] proposed that this DDI is rare. In
conclusion, the occurrence of respiratory arrest during the
coadministration of benzodiazepines and clozapine appears
to be a very rare idiosyncratic reaction in the first days of
clozapine treatment. The most reasonable explanation of this
DDI is that clozapine and benzodiazepines may have additive
properties at the GABA receptors which manifest in this way
in rare individuals.
3.4.3. Flumazenil Treatment of Drug Intoxication after Adding
Clozapine to Low Benzodiazepine Doses. Peetoom and
Schulte [43] published 2 cases in which flumazenil reversed
comas secondary to adding clozapine to low doses of
Case Reports in Psychiatry 9
benzodiazepines. A 77-year-old female was taking other
medications and 20mg/day of oxazepam, but she went into
a coma after erroneously taking 100mg clozapine, 10mg
oxazepam, and 400mg norfloxazine. She quickly recovered
from the coma with 0.5mg of flumazenil. A 44-year-old
female with Huntington’s disease was taking 6mg/day of
diazepamand 75mg/day of oxazepamand othermedications.
She was titrated to 175mg/day of clozapine within 14 days
and went into a coma 2 hours after administration of her
benzodiazepine medications. The patient awoke from the
coma after the administration of 0.5mg flumazenil [43].
That a coma induced by the combination of clozapine and
benzodiazepines responded to flumazenil suggests that the
coma may be explained by the additive effects of these drugs
at the GABA receptors.
3.4.4. GABAMechanisms and Catatonia Secondary to Clozap-
ineWithdrawal. According to the literature, dysregulation of
the GABA receptors may contribute to catatonia. Hauser et
al. [44] and Rosebush and Mazurek [45] described catatonic
episodes during sudden benzodiazepine withdrawal. Carroll
[46] described a patient with no previous history of cata-
tonia who developed catatonia after abrupt withdrawals of
benzodiazepines (GABAA allosteric agonists) and baclofen
(GABAB agonist) [46]. In a review of catatonia after sedative
withdrawal, Oldham and Desan [47] reviewed prior pub-
lished cases and added new ones including 16 cases of ben-
zodiazepines, 4 cases of benzodiazepines mixed with other
sedative drugs, and 6 cases of alcohol withdrawal. Similar to
the benzodiazepines, ethanol had also been described as an
allosteric GABAA agonist [48] and chronic alcoholism had
been associated with GABAA downregulation [47]. Oldham
and Desan proposed that catatonia and delirium may be
a spectrum of disorders associated with GABA receptor
dysregulation [47].
In summary, if clozapine has GABA agonist properties,
sudden clozapine withdrawal may explain GABA dysreg-
ulation with sudden decrease in GABA activity that may
contribute to the development of catatonic symptoms in
vulnerable patients. In that sense, based on prior cases and on
our case, the treatment for catatonia secondary to clozapine
can be benzodiazepines and/or restarting clozapine. In the
USA, there is no parenteral clozapine; therefore, parenteral
benzodiazepines may be required if the patient cannot take
oral clozapine.
3.5. Limitations. The most important limitation of this case
description is that the chart data is not detailed enough
to know how catatonic symptoms responded to treatment
in all 3 catatonic episodes. Ideally, one would have liked
to have catatonia scales, standardized treatments not by
multiple physicians, and exact descriptions of symptom onset
before coming to medical attention. Even with its limita-
tions, this is the first article with a careful description of 3
repeated episodes of catatonia secondary to sudden clozapine
withdrawal and it includes a careful follow-up for decades
(Figure 2), which is very rare in published case reports in
psychiatry.
4. Conclusion
The LADRCAT was modified to assess ADRs secondary to
drug withdrawal. This modified scale was used to assess 7
previously published cases of catatonia secondary to clozap-
ine withdrawal and established that 3 were definitive and 4
probable. Another definitive case was described with three
catatonic episodes which (1) occur after sudden discontin-
uation of clozapine in the context of decades of follow-up,
(2) had ≥3 of 12 DSM-5 catatonic symptoms and serum
CK elevation, and (3) required medical hospitalization and
IV fluids. Clozapine may be a GABA agonist and sudden
clozapine withdrawal may explain a sudden decrease in
GABA activity that may contribute to the development of
catatonic symptoms in vulnerable patients. Based on prior
cases and on our case, the treatment for catatonia secondary
to sudden clozapine withdrawal can be benzodiazepines
and/or restarting clozapine.
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